Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Tailored Void-Labels: The Appropriate Effect for Every Application
Monday, April 03, 2023The volume of the worldwide counterfeit medicines market amounts to about billion US dollars Every year it grows by about percenttwice as fast as the legal medicines market Counterfeits and tampering pose potential health risks to patients The cons...
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
Monday, April 03, 2023Enlivex Therapeutics Ltd a clinicalstage macrophage reprogramming immunotherapy company today announced a clinical collaboration with BeiGene to evaluate the safety and efficacy of Allocetra an investigational macrophagereprogramming cell therapy in...
Adiso Therapeutics Announces Participation at Healthruption, Goldman Sachs Second Annual Healthcare Disruption Conference
Saturday, April 01, 2023Adiso Therapeutics Inc a clinicalstage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families today announced that Scott Megaffin Chief Executive Officer has been in...
Orion is building a unique pharmaceutical research ecosystem in Finland – using data and artificial intelligence to shorten the development time of new innovative medicines
Thursday, March 30, 2023Orion is launching a project to build a unique data and AIbased pharmaceutical research ecosystem in Finland in cooperation with other companies research institutes and universities Business Finland has granted nearly EUR million in funding to Orion...
Cosmo announces Territory Expansion Agreement For Lumeblue™ (Methylene Blue MMX™) With China Medical System Holdings
Thursday, March 30, 2023Cosmo Pharmaceuticals NV today announced the territory expansion of the license agreement for Lumeblue with China Medical System Holdings Limited CMS SEHK The expansion goes beyond the existing licensed territories Greater China including the mainla...
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
Wednesday, March 29, 2023Entrada Therapeutics Inc a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle EEV therapeutics as a new class of medicines today announced that Dipal Doshi President and Chief Ex...
Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics
Wednesday, March 29, 2023Axial Therapeutics a clinicalstage biopharmaceutical company dedicated to the development of guttargeted small molecule therapeutics for neurological conditions and oncology today announced key promotions in its research and development organization...
AmbioPharm To Utilize YMC Twin-Column Chromatography in Large Scale Peptide Production
Tuesday, March 28, 2023AmbioPharm a worldwide leader in peptide API CDMO services announces the acquisition of new disruptive peptide purification technology developed by YMC which leverages several of YMCs patented twincolumn purification processes Twincolumn chromatograp...
Vetter Performs Extraordinarily with Six Wins in the 12th Annual CDMO Leadership Awards
Tuesday, March 28, 2023Vetter a globally operating Contract Development and Manufacturing Organization CDMO earned the esteemed CDMO Leadership Awards in all six core categories quality expertise reliability capabilities compatibility and service In addition the company...
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
Monday, March 27, 2023Cullinan Oncology Inc a biopharmaceutical company focused on modalityagnostic targeted oncology therapies today announced the US Food and Drug Administration FDA has cleared its Investigational New Drug IND application for CLN a fusion protein compri...
